RXRX ▼ -5.5% - Recursion Pharmaceuticals, Inc. $RXRX - Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair 02-NOV-2026 04:30 PM ET